Market Research Assistance
- + 1-888-391-5441
- sales@rnrmarketresearch.com
On the Web 
Respiratory therapeutics Market Research Reports
Respiratory therapeutics Market Research Reports
| Title | published | price | |
|---|---|---|---|
Dyspnea-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016By Delve Insight "...... ve of the Dyspnea Report is to understand the market and pipeline status of the drugs around the Dyspnea to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline strategies. The......" | 01-Sep-2016 | $2000 | |
Bronchitis - Market Insights, Epidemiology and Market Forecast-2023By Delve Insight "...... United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Bronchitis forecasted market share for ten years to 2023 segmented by seven major ma......" | 01-Sep-2016 | $4950 | |
Chronic Bronchitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016By Delve Insight "...... key objective of the Chronic Bronchitis Report is to understand the market and pipeline status of the drugs around the Chronic Bronchitis to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on d......" | 01-Sep-2016 | $2000 | |
Chronic Obstructive Pulmonary Disease (COPD)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016By Delve Insight "...... urers across the globe. A key objective of the Chronic Obstructive Pulmonary Disease (COPD) Report is to understand the market and pipeline status of the drugs around the Chronic Obstructive Pulmonary Disease (COPD) to explore the generic development......" | 01-Sep-2016 | $2000 | |
Lower Respiratory Tract Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016By Delve Insight "...... ss the globe. A key objective of the Lower Respiratory Tract Infections Report is to understand the market and pipeline status of the drugs around the Lower Respiratory Tract Infections to explore the generic development opportunities, licensing oppo......" | 01-Sep-2016 | $2000 | |
Respiratory Tract Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016By Delve Insight "...... globe. A key objective of the Respiratory Tract Infections Report is to understand the market and pipeline status of the drugs around the Respiratory Tract Infections to explore the generic development opportunities, licensing opportunities and to g......" | 01-Sep-2016 | $2000 | |
Respiratory Distress Syndrome-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016By Delve Insight "...... e globe. A key objective of the Respiratory Distress Syndrome Report is to understand the market and pipeline status of the drugs around the Respiratory Distress Syndrome to explore the generic development opportunities, licensing opportunities and t......" | 01-Sep-2016 | $2000 | |
Respiratory Hypersensitivity-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016By Delve Insight "...... globe. A key objective of the Respiratory Hypersensitivity Report is to understand the market and pipeline status of the drugs around the Respiratory Hypersensitivity to explore the generic development opportunities, licensing opportunities and to g......" | 01-Sep-2016 | $2000 | |
Respiratory Syncytial Virus (RSV) Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016By Delve Insight "...... urers across the globe. A key objective of the Respiratory Syncytial Virus (RSV) Infections Report is to understand the market and pipeline status of the drugs around the Respiratory Syncytial Virus (RSV) Infections to explore the generic development......" | 01-Sep-2016 | $2000 | |
Upper Respiratory Tract Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016By Delve Insight "...... ss the globe. A key objective of the Upper Respiratory Tract Infections Report is to understand the market and pipeline status of the drugs around the Upper Respiratory Tract Infections to explore the generic development opportunities, licensing oppo......" | 01-Sep-2016 | $2000 | |
| | |||